TIMAR1: Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
Study Details
Study Description
Brief Summary
The study hypothesis is that new imaging agents [203Pb]VMT01 and [68Ga]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging modalities respectively.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Detailed Description
This is a first-in-human study evaluating the suitability of [203Pb]VMT01 for SPECT/CT imaging and [68Ga]VMT02 for PET/CT imaging of MC1R-expressing metastatic melanoma. Study results will provide foundational data to develop imaging and dosing for future therapeutic trials of [212Pb]VMT01 for the treatment of metastatic melanoma.
The study will be a cross-over study with the participants serving as their own comparator. Participants with positive FDG-PET scans for stage IV (or inoperable stage III) metastatic melanoma will undergo SPECT/CT scans utilizing [203Pb]VMT01 followed a few weeks later by PET/CT scans utilizing [68Ga]VMT02, or vice versa. The order of the imaging agents will be randomly assigned.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: [203Pb]VMT01 first Participants randomized to this arm will receive imaging agent [203Pb]VMT01 and undergo SPECT/CT imaging first. Later, participants in this arm will receive [68Ga]VMT02 and undergo PET/CT imaging. |
Drug: [203Pb]VMT01
Diagnostic imaging radiopharmaceutical; by intravenous infusion
Drug: [68Ga]VMT02
Diagnostic imaging radiopharmaceutical; by intravenous infusion
|
Active Comparator: [68Ga]VMT02 first Participants randomized to this arm will receive imaging agent [68Ga]VMT02 and undergo PET/CT imaging first. Later, participants in this arm will receive [203Pb]VMT01 and undergo SPECT/CT imaging. |
Drug: [203Pb]VMT01
Diagnostic imaging radiopharmaceutical; by intravenous infusion
Drug: [68Ga]VMT02
Diagnostic imaging radiopharmaceutical; by intravenous infusion
|
Outcome Measures
Primary Outcome Measures
- Number of Participants with Study Imaging Agent-Associated Adverse Events (AE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. [Visit 1 (Day 1) through Visit 5 (approximately Day 60 but could extend up to Day 108); ongoing Serious Adverse Events (SAE) will be followed for no longer than Day 65 or 30 days from the date of the SAE report (whichever is later).]
Adverse Events (AEs) will be assessed for severity according to CTCAE v5.0 and for relatedness to each of the investigative imaging agents ([203Pb]VMT01 and [68Ga]VMT02). Assessments attributed as possibly, probably, or definitely related to the imaging agent will be considered related.
- Biodistribution of [68Ga]VMT02 [12 hours]
Biodistribution will be calculated by utilizing PET/CT scans.
- Biodistribution of [203Pb]VMT01 [24 hours]
Biodistribution will be calculated by utilizing SPECT/CT scans.
- Peak Plasma Concentration (Cmax) of [203Pb]VMT01 [24 hours]
Cmax will be determined by blood sampling and direct radioactivity measurements.
- Area Under the Plasma Concentration Versus Time Curve (AUC) for [203Pb]VMT01 [24 hours]
AUC will be determined by blood sampling and direct radioactivity measurements.
- Renal Excretion of [203Pb]VMT01 [24 hours]
Renal excretion will be determined by urine sampling and direct radioactivity measurements.
- Modeling of [203Pb]VMT01 Dosimetry [24 hours]
Dosimetry will be modeled by utilizing the SPECT/CT scans.
Secondary Outcome Measures
- MC1R Expression Correlation Between Archived Tumor Tissue and Study Imaging [Historical tissue sample (collected <365 days before study enrollment) compared to Visit 1 (Day 1) and Visit 3 (Day 21-34) imaging]
Archived (previously collected) tumor tissue will be tested for MC1R expression and compared to study images obtained using MC1R targeted imaging agents, [203Pb]VMT01 and [68Ga]VMT02. The data will be assessed for an association between positive tissue and positive images.
- Cancer Site Correlation Between Standard of Care Imaging Compared to Study Imaging [Historical imaging information compared to Visit 1 (Day 1) and Visit 3 (Day 21-34) imaging]
Sites of cancer detected previously by imaging will be compared to the presence or absence of positive imaging scans with the study agents, [203Pb]VMT01 and [68Ga]VMT02.
- Dosimetry will be Calculated for each Study Imaging Agent by Measuring the Cumulative Absorbed Dose of Radiation to the Participant's Individual Organs and Tumors [Visit 1 (Day 1) and Visit 3 (Day 21-34) imaging]
For a given participant, dosimetry calculations will be compared between the two imaging agents with respect to cumulative absorbed dose of radiation.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosed with Stage IV metastatic melanoma, or inoperable Stage III equivalent
-
Baseline fluorodeoxyglucose (FDG)-PET scan available from within 30 days prior to date of enrollment
-
Blood counts and metabolic results within protocol limits within 14 days prior to enrollment
-
Ability to lie flat and still for a minimum of two hours for imaging
-
Male and female participants with reproductive potential must agree to use highly effective contraception in preparation of the study, during the study, and for 4 weeks following the last dose of an investigative imaging agent
-
Documented life expectancy of at least 3 months
Exclusion Criteria:
-
Active secondary malignancy
-
Prior treatment (for any reason) with radioactive nuclides; imaging tracers are acceptable
-
Pregnancy or breast feeding a child
-
Uncontrolled infection
-
Treatment with another investigational drug within 30 days prior to enrollment date
-
Any treatment with BRAF inhibitors since the baseline FDG-PET scan or plans for such treatment during the study
-
Kidney function not within protocol limits
-
BMI>40 kg/m2
-
History of a condition resulting in anaphylaxis or angioedema
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Mayo Clinic | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Viewpoint Molecular Targeting
- Mayo Clinic
Investigators
- Principal Investigator: Frances L Johnson, MD, Viewpoint Molecular Targeting
- Principal Investigator: Geoffrey B Johnson, MD, PhD, Mayo Clinic
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TIMAR1